目的 探討虎杖葉膠囊聯(lián)合硝苯地平緩釋片（Ⅱ）治療肝陽上亢型原發(fā)性高血壓的臨床療效。方法 選取2019年6月1日—2019年12月1日于南陽市中心醫(yī)院心血管內(nèi)科就診的160例肝陽上亢型原發(fā)性高血壓患者作為研究對象。將所有患者隨機分為對照組和治療組，每組各80例。對照組口服硝苯地平緩釋片（Ⅱ），1片/次，2次/d；治療組在對照組的基礎上口服虎杖葉膠囊，2粒/次，2次/d。兩組均治療3個月。觀察兩組臨床療效，比較兩組中醫(yī)癥候積分、收縮壓和舒張壓降低值、動脈脈搏傳導速度、血清血管內(nèi)皮細胞功能指標水平。結果 治療后，與對照組（80.00%）相比，治療組患者總有效率（92.50%）顯著升高，差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組患眩暈積分、頭痛積分、急躁易怒積分均顯著下降（P<0.05），且治療組中醫(yī)證候積分明顯低于對照組，差異具有統(tǒng)計學意義（P<0.05）。治療后，與對照組相比，治療組收縮壓和舒張壓降低值均顯著升高，差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組頸-股動脈脈搏傳導速度（cfPWV）、踝-肱動脈脈搏傳導速度（baPWV）均顯著降低，差異具有統(tǒng)計學意義（P<0.05），且治療組cfPWV和baPWV明顯低于對照組，差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組患者內(nèi)皮素（ET）水平顯著降低，一氧化氮（NO）水平均顯著升高（P<0.05），且治療組ET水平降低更為明顯，NO水平升高更加明顯，差異具有統(tǒng)計學意義（P<0.05）。結論 虎杖葉膠囊聯(lián)合硝苯地平緩釋片治療肝陽上亢型原發(fā)性高血壓安全有效，可降低血壓和中醫(yī)癥候積分，改善血管彈性水平，其降壓機制可能與改善血管內(nèi)皮細胞功能有關。

Objective To investigate the clinical efficacy of Huzhangye Capsules combined with Nifedipine Sustained-release Tablets (Ⅱ) in treatment of primary hypertension with liver Yang hyperactivity. Methods Patients (160 cases) with primary hypertension with liver Yang hyperactivity in the Department of Cardiovascular Disease of Nanyang Central Hospital from June 1, 2019 to December 1, 2019 were enrolled. All patients were randomly divided into control and treatment groups, and each group had 80 cases. Patients in the control group were po administered with Nifedipine Sustained-release Tablets (Ⅱ), 1 tablets/time, three times daily. Patients in the treatment group were po administered with Huzhangye Capsules on the basis of the control group, 2 grains/time, twice daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and the scores of TCM syndrome, the reduction of systolic and diastolic blood pressure, the arterial pulse conduction velocity, and the serum levels of vascular endothelial cell function indexes in two groups were compared. Results After treatment, compared with the control group (80.00%), the total effective rate of the treatment group (92.50%) was significantly increased, and the difference was statistically significant (P<0.05). After treatment, the vertigo score, headache score, irritability score of two groups were significantly decreased (P<0.05), and the score of TCM syndrome in the treatment group was significantly lower than that of the control group, and the difference was statistically significant (P<0.05). After treatment, compared with the control group, the decreased values of systolic and diastolic blood pressure in the treatment group were significantly increased, and the difference was statistically significant (P<0.05). After treatment, the levels of cfPWV and baPWV in two groups were significantly decreased (P<0.05), and the decrease of cfPWV and baPWV in the treatment group was significantly lower than that in the control group, the difference was statistically significant (P<0.05). After treatment, the level of ET in two groups were significantly decreased, but the level of NO were significantly increased (P<0.05), and the level of ET in the treatment group was significantly lower than that in the control group, while the level of NO in the treatment group was significantly higher than that in the control group, and the difference was statistically significant (P<0.05). Conclusion Huzhangye Capsules combined with Nifedipine Sustained-release Tablets (Ⅱ) is safe and effective in treatment of primary hypertension with liver Yang hyperactivity, which can reduce blood pressure and the score of TCM syndrome, and improve the level of vascular elasticity. Its antihypertensive mechanism may be related to improving the function of vascular endothelial cells.

R972